Thiourea and benzamide compounds, composition and methods of treating or preventing inflammatory diseases and atherosclerosis

Bibliography

• BRASH AR: Lipoxygenases: occurrence, functions, catalysis and acquisition of substrate. J. Biol. Chem. (1999) 274:23679–23682.
   PubMed Web of Science ®Google Scholar
• •Most recent review on LO heterogeneity and function of the isoenzymes
   Google Scholar
• KUHN H, THIELE BJ: The diversity of the lipoxygenase family. Many sequence data but little information on biological significance. FEBS Lett. (1999) 449:7–11.
   Google Scholar
• SIGAL E, GRUNBERGER, CRAIK CS, CAUGHEY GH, NADELJA: Arachidonate 15-lipoxygenase (omega-6 lipoxygenase) from human leukocytes. Purification and structural homology to other mammalian lipoxy-genases. j Biol. Chem. (1988) 263:5328–5332.
   Google Scholar
• BRASH AR, BOEGLIN WE, CHANG MS: Discovery of a second 15S-lipoxygenase in humans. Proc. Natl. Acad. Sci. USA (1997) 94:6148–6152.
   PubMed Web of Science ®Google Scholar
• KCJEIN H, SCHEWE T, RAPOPORT SM: The stereochem-istry of the reaction of lipoxygenases and their metabolites. A proposed nomenclature for lipoxyge-nases and related enzymes. Adv. Enzymol. (1986) 58:273–311.
   PubMedGoogle Scholar
• LEHMANN WD: Regio- and stereochemistry of thedioxygenation reaction catalyzed by (S)-type lipoxyge-nases or by the cyclooxygenase activity of prosta-glandin H synthases. Free Radic. Biol. Med. (1994) 16:241–253.
   PubMed Web of Science ®Google Scholar
• GILLMOR SA, VILLASENOR A, FLETTERICK R, SIGAL E, BROWNER MF: The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nature Struct. Biol. (1997) 4:1003–1009.
   PubMedGoogle Scholar
• •First x-ray structure of a mammalian LO.
   Google Scholar
• MCMILLAN RM, WALKER ERH: Designing therapeuti- cally effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sc1 13:323-330 77777
   Google Scholar
• DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl. J. Med. (1999) 340:197–206.
   PubMed Web of Science ®Google Scholar
• HIGGS GA, SALMON JA, SPAYNE JA: The inflammatory effects of hydroperoxy and hydroxy acid products of arachidonate lipoxygenase in rabbit skin. Br. J. Pharmac. (1981) 74:429–433.
   PubMed Web of Science ®Google Scholar
• RAMIS I, CATAFAU JR, SERRA J, BULBENA O, PICADO C, GELP E: In vivo release of 15-HETE and other arachi-donic acid metabolites in nasal secretion during early allergic response. Prostaglandins (1991) 42:411–420.
   PubMed Web of Science ®Google Scholar
• HENRICKS PA, ENGELS F, VAN DER VLIET H, NIJKAMP FP: 9- and 13-hydroxy-linoleic acid possess chemotactic activity for bovine and human polymorphonuclear leukocytes. Prostaglandins (1991) 41:21–27.
   PubMed Web of Science ®Google Scholar
• YLA-HERTTUALA S, ROSENFELD M, PARTHASARATHY S et al.: Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J. Clin. Invest. (1991) 87:1146–1152.
   Google Scholar
• KUHN H, BELKNER J, ZAISS S, FAHRENKLEMPER T, WOHLFEIL S: Involvement of 15-lipoxygenase in early stages of atherogenesis. J. Exp. Med. (1 9 9 4) 179:1903-1911.
   Google Scholar
• KUHN H: Inhibitors of 12/15-lipoxygenase arepotential anti-atherosclerotic drugs. Curr. Opin. Invest. Drugs (1999) 1:227–237.
   Google Scholar
• •Summarises the challenges in the development of LO inhibi-tors as anti-atherosclerotic drugs.
   Google Scholar
• CYRUS T, WITZTUM JL, RADER DJ et al.: Disruption of thel2/15-LOX gene diminish atherosclerosis in apolipoprotein E deficient mice. J. Clin. Invest. (1999) 103:1597–1604.
   PubMed Web of Science ®Google Scholar
• ••Indicates the pro-atherogenic role of 12/15-LO in a murineatherosclerosis model.
   Google Scholar
• SHEN J, HENDERICK E, CORNHILL F et al: Macrophage- mediated 15-lipoxygernase expression protects against atherosclerosis development. J. Clin. Invest. (1996) 98:2201–2208.
   PubMed Web of Science ®Google Scholar
• ••Indicates the anti-atherogenic role of 12/15-LO in two rabbitatherosclerosis models.
   Google Scholar
• DEL-RIO M, CHULIA T, RUIZ E, TEJERINA T: Action of probucol in arteries from normal and hypercholes-terolemic rabbits. Br. J. Pharmacol. (1996) 118:1639–1644.
   PubMed Web of Science ®Google Scholar
• BIRD DA, TANGIRALA RK, FRUEBIS J, STEINBERG D, WITZTUM JL, PALINSKI W: Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. (1998) 39:1079–1090.
   PubMed Web of Science ®Google Scholar
• HOLTZMAN MJ, ZHANG V, HUSSAIN H, ROSWIT WT, WILSON JD: Prostaglandin H synthase and lipoxyge-nase gene families in the epithelial cell barrier. Ann. NY Acad. Sci. (1994) 744:58–77.
   PubMed Web of Science ®Google Scholar
• MUNGER K, MONTERO A, FUKUNAGA M et al.: Transfec-tion of rat kidney with the human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl Acad. Sci. USA (199) 96:13375–13380.
   Google Scholar
• •Indicates the anti-inflammatory effect of 15-LO expression in rat glomerulonephritis.
   Google Scholar
• BOEGLIN WE, KIM RB, BRASH AR: A 12R-lipoxygenase in human skin: mechanistic evidence, molecular cloning, and expression. Proc. Natl. Acad. ScL USA (1998) 95:6744–6749.
   PubMed Web of Science ®Google Scholar
• KeHN H, BARNETT J, GRUNBERGER D et al.: Overexpres-sion, purification and characterization of human recombinant 15-lipoxygenase. Biochim. Biophys. Acta (1993) 1169:80–89.
   PubMed Web of Science ®Google Scholar
• DENIS D, FALGUEYRET JP, RIENDEAU D, ABRAMOVITZ M: Characterization of the activity of purified recombi-nant human 5-lipoxygenase in the absence and presence of leukocyte factors. J. Biol. Chem. (1991) 266:5072–5079.
   PubMed Web of Science ®Google Scholar
• CHEN XS, BRASH AR, FUNK CD: Purification and charac-terization of recombinant histidine-tagged human platelet 12-lipoxygenase expressed in a baculovirus/insect cell system. Eur. j Biochem. (1993) 214:845–852.
   PubMedGoogle Scholar